Diabetic Retinopathy Pipeline Insights | Clinical Trials Evaluation Report 2022 by DelveInsight

2022年05月31日01:00

Diabetic Retinopathy Pipeline involves 80+ key companies continuously working towards developing 80+ Diabetic Retinopathy treatment therapies, as per DelveInsight

Las Vegas, USA, May 30, 2022 (GLOBE NEWSWIRE) -- Diabetic Retinopathy Pipeline Insights | Clinical Trials Evaluation Report 2022 by DelveInsight

Diabetic Retinopathy Pipeline involves 80+ key companies continuously working towards developing 80+ Diabetic Retinopathy treatment therapies, as per DelveInsight

DelveInsight’s Diabetic Retinopathy Pipeline Insight 2021 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Diabetic Retinopathy pipeline domain.

Some of the essential takeaways from the Diabetic Retinopathy Pipeline report:

  • DelveInsight’s Diabetic Retinopathy Pipeline analysis depicts a robust space with 80+ active players working to develop 80+ pipeline treatment therapies.
  • Some of the key Diabetic Retinopathy Pipeline companies working to develop potential drug candidates to improve the Diabetic Retinopathy treatment scenario include Kodiak Sciences, Novartis, Bayer, RemeGen, Aerpio Therapeutics, Hoffman-La-Roche, Regenxbio Inc., Apexian Pharmaceuticals, Inc., Ocuphire Pharma, Inc., Adverum Biotechnologies, Oxurion, MingSight Relin Pharmaceuticals, Boehringer Ingelheim, NovaGo Therapeutics, RIBOMIC, Retinset SL, PYC Therapeutics, PharmAbcine, Palatin Technologies, LUYE PHARMA, Curacle, BONAC corporation, AptaBio Therapeutics, Ascentage Pharma, EyeGene, Applied Therapeutics, Foresee Pharmaceuticals, Glycadia, Everglades Biopharma, Novelty Nobility Inc, Noveome Biotherapeutics, Shanghai Henlius Biotech, EyePoint Pharmaceuticals and several others.
  • Essential Diabetic Retinopathy therapies such as KSI-301, Brolucizumab, Runcaciguat, RC 28 E, AKB-9778, RG7774, RGX-314, APX3330, ADVM-022, THR-687, OCX 063, BI 764524, MS-553, NG004, RBM-008, BSL01, PYC001, PMC 403, PL8177, PL9654, LY-09004, CU 06, BNC-1601, APX 1004, UBX 1967, EG-Mirotin, AT 003, FP-008, GLY-230, HLX 04,EYP-1901 and many others.
  • In May 2022, EyePoint Pharmaceuticals announced the EYP-1901 license to Betta Pharmaceuticals, to develop and commercialize EYP-1901 in China, Hong Kong, Macau, and Taiwan. EyePoint retains all rights for EYP-1901 in the rest of the world and expands its exclusive rights to local delivery of vorolanib for the treatment of all ophthalmic diseases, including diabetic macular edema (DME). Phase 2 clinical trial for EYP-1901 in non-proliferative diabetic retinopathy (NPDR) is expected to initiate in 2H 2022.
  • In April 2022, Ocuphire Pharma presented masked safety data from the ongoing ZETA-1 Phase 2b trial of oral APX3330 for the treatment of diabetic retinopathy. The results show a favorable ophthalmic and systemic safety and tolerability profile, consistent with 11 prior safety trials of APX3330 in non-ophthalmic indications. The company expects to report top-line results from the ZETA-1 trial in the second half of 2022.
  • In January 2022, Ocuphire Pharma entered into an agreement with Apexian Pharmaceuticals, Inc., granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications.
  • The Therapeutic candidate KSI-301, currently in clinical development being produced by Kodiak Sciences is a novel anti-VEGF biologic designed to have an extended ocular half-life. KSI-301 is being developed in Phase III stage of Diabetic Retinopathy Pipeline development towards a once every four to six-month treatment regimen – a possible game changer that may provide the opportunity for real prevention.
  • Brolucizumab (RTH258) is a humanized single-chain antibody fragment (scFv) and the most clinically advanced, humanized single-chain antibody fragment developed by Novartis. Currently, it is in the Phase III stage of development to treat Diabetic Retinopathy.
  • In September 2021, AbbVie and REGENXBIO entered into a strategic partnership combining eye care and gene therapy expertise to develop and commercialize RGX-314, investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases. REGENXBIO to receive $370 million upfront payment from AbbVie.
  • REGENXBIO announced additional positive interim data from the ongoing Phase II ALTITUDE trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery. RGX-314 continues to be well tolerated at six months following a one-time, in-office injection, with nearly 50 percent of patients dosed with RGX-314 in Cohort 1 demonstrating a clinically meaningful improvement from baseline.

Request a sample and discover more about the report offerings @ Diabetic Retinopathy Emerging Therapies

The Diabetic Retinopathy pipeline report lays down detailed profiles of the pipeline assets, comparative analysis of clinical and non-clinical stage Diabetic Retinopathy products, inactive and dormant assets, and a comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Diabetic Retinopathy pipeline landscape.

Diabetic Retinopathy Overview

Diabetic Retinopathy is a serious sight-threatening complication of Diabetes. Diabetes interferes with the body's ability to use and store sugar (glucose). The disease is characterized by too much sugar in the blood, which can cause damage throughout the body, including the eyes. Diabetic Retinopathy Symptoms include spots or dark strings floating in your vision (floaters), blurred and fluctuating vision, dark or empty areas in your vision as well as vision loss. There are 4 Diabetic Retinopathy Stages including Mild Non Proliferative Diabetic Retinopathy, Moderate Non Proliferative Diabetic Retinopathy, Severe Non Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy. Diabetic Retinopathy risk factors include independent aspects such as hypertension, duration of diabetes, diabetic neuropathy, diabetic nephropathy, diabetic foot ulcer, foot amputation, fasting blood glucose, serum total cholesterol, serum triglyceride, and HbA1c. Retinal photography and digital imaging are considered to be effective technique for Diabetic Retinopathy screening. Over time, Diabetes damages small blood vessels throughout the body, including the retina. Diabetic Retinopathy occurs when these tiny blood vessels leak blood and other fluids. Diabetic Retinopathy causes the retinal tissue to swell, resulting in cloudy or blurred vision. Diabetic Retinopathy usually affects both eyes. The longer a person has diabetes, the more likely they will develop Diabetic Retinopathy. If left untreated, Diabetic Retinopathy can even cause blindness.

Understand more about the very common Diabetic disease @ Diabetic Retinopathy Pipeline Drugs Assessment

Diabetic Retinopathy Pipeline Drugs

DrugCompanyPhaseMoARoA
KSI-301Kodiak Sciences Phase III Vascular endothelial growth factors inhibitor Intravitreal
BrolucizumabNovartis Phase III Vascular endothelial growth factor A inhibitor Intravitreal
RuncaciguatBayer Phase II Guanylate cyclase stimulant Oral
RC 28 ERemeGen Phase II Vascular endothelial growth factors inhibitor Intravitreal
RG7774Hoffman-La-Roche Phase II Cannabinoid receptor CB2 agonist Oral
RGX-314Regenxbio Inc. Phase II Vascular endothelial growth factors inhibitor Suprachoroidal Delivery
APX3330Apexian Pharmaceuticals, Inc. Phase II DNA apurinic apyrimidinic site lyase inhibitor Oral
ADVM-022Adverum Biotechnologies Phase II Vascular endothelial growth factor A inhibitor Intravitreal
THR-687Oxurion Phase II Integrin inhibitor Intravitreal
OCX 063OccuRx Preclinical Angiogenesis inhibitor NA
BI 764524Boehringer Ingelheim Phase I/II NA Intravitreal
MS-553MingSight Pharmaceuticals Phase I Protein kinase C beta inhibitor Oral
APX-1004AptaBio Therapeutics Phase I NADPH oxidase inhibitor NA
EG-MirotinEyeGene Phase II Platelet derived growth factor stimulant Intramuscular
AT 003Applied Therapeutics Preclinical Aldehyde reductase inhibitor Oral
GLY-230Glycadia Phase I Glycosylation inhibitor Oral

Learn more about the novel and emerging Proliferative Diabetic Retinopathy as well as Non Proliferative Diabetic Retinopathy drugs @ Diabetic Retinopathy Pipeline Analysis

Diabetic Retinopathy Therapeutics Assessment

The Diabetic Retinopathy Pipeline report proffers an integral view of the Diabetic Retinopathy emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

Scope of the Diabetic Retinopathy Pipeline Report

  • Coverage: Global
  • Therapeutic Assessment By Diabetic Retinopathy Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Diabetic Retinopathy Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration, Inactive candidates
  • Therapeutics AssessmentBy Diabetic Retinopathy Route of Administration: Oral, Parenteral, Intravitreal, Subretinal, Topical
  • Therapeutics AssessmentBy Diabetic Retinopathy Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
  • Therapeutics AssessmentBy Diabetic Retinopathy Mechanism of Action: Vascular endothelial growth factor A inhibitors, Guanylate cyclase stimulant, Angiogenesis inhibitor, Cell adhesion molecule inhibitor, TIE-2 receptor agonist, Melanocortin type 1 receptor agonist, NADPH oxidase inhibitors, Proto-oncogene protein c-bcl-2 inhibitors, Protein kinase C beta inhibitors, Integrin inhibitors, DNA apurinic apyrimidinic site lyase inhibitors and Vascular endothelial growth factors inhibitor
  • Key Diabetic Retinopathy Companies: Kodiak Sciences, Novartis, Bayer, RemeGen, Aerpio Therapeutics, Hoffman-La-Roche, Regenxbio Inc., Apexian Pharmaceuticals, Inc., Ocuphire Pharma, Inc., Adverum Biotechnologies, Oxurion, MingSight Relin Pharmaceuticals, Boehringer Ingelheim, NovaGo Therapeutics, RIBOMIC, Retinset SL, PYC Therapeutics, PharmAbcine, Palatin Technologies, LUYE PHARMA, Curacle, BONAC corporation, AptaBio Therapeutics, Ascentage Pharma, EyeGene, Applied Therapeutics, Foresee Pharmaceuticals, Glycadia, Everglades Biopharma, Novelty Nobility Inc, Noveome Biotherapeutics, Shanghai Henlius Biotech, EyePoint Pharmaceuticals and several others.
  • Key Diabetic Retinopathy Pipeline Therapies: KSI-301, Brolucizumab, Runcaciguat, RC 28 E, AKB-9778, RG7774, RGX-314, APX3330, ADVM-022, THR-687, OCX 063, BI 764524, MS-553, NG004, RBM-008, BSL01, PYC001, PMC 403, PL8177, PL9654, LY-09004, CU 06, BNC-1601, APX 1004, UBX 1967, EG-Mirotin, AT 003, FP-008, GLY-230, HLX 04, EYP-1901, and others.

Dive deep into rich insights for emerging therapies and assessment, visit @ Diabetic Retinopathy Pipeline Drugs

Table of Contents

1 Introduction
2 Executive Summary
3 Diabetic Retinopathy: Overview
4 Pipeline Therapeutics
5 Late Stage Products (Phase III)
5.1 KSI-301: Kodiak Sciences
6 Mid Stage Products (Phase II)
6.1 RC28-E: RemeGen
7 Early Stage Products (Phase I/II)
7.1 BI 764524: Boehringer Ingelheim
8 Therapeutic Assessment
9 Inactive Products
10 Collaborations Assessment- Licensing / Partnering / Funding
11 Diabetic Retinopathy- Unmet Needs
12 Diabetic Retinopathy- Market Drivers and Barriers
13 Appendix
14 About DelveInsight

For further information on the Diabetic Retinopathy current pipeline therapeutics, reach out @ Diabetic Retinopathy Ongoing Clinical Trials

Related Reports

Diabetes Pipeline

DelveInsight’s, “Diabetes Pipeline Insights, 2022,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products and key companies involved such as Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, and many more.

Chronic Pain associated with Painful Diabetic Neuropathy Market

DelveInsight’s ‘Chronic Pain associated with Painful Diabetic Neuropathy- Market Insight, Competitive Landscape and Market Forecast, 2026’ report delivers an in-depth understanding of Chronic Pain associated with Painful Diabetic Neuropathy covering the market trends, market drivers, market barriers and key companies involved such as Janssen Pharmaceuticals, Grunethal, Pfizer, Eli Lilly, Shionogi, Ono pharmaceuticals, Fremslife S.r.l, Helixmith, Aptinyx, Regenacy Pharmaceuticals, Novaremed, Nevro Corp, Erchonia Corporation, and others.

Injectable Drug Delivery Devices Market

Global Injectable Drug Delivery Devices Market was valued at USD 17.65 billion in 2020, growing at a CAGR of 11.25% during the forecast period from 2021 to 2026, to reach USD 33.37 billion by 2026. The report delivers an in-depth understanding of Injectable Drug Delivery Devices and the historical and forecasted market trends, market drivers, market barriers and key companies involved such as Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Johnson & Johnson, Antares Pharma, AbbVie Inc, Pfizer Inc, Mylan N.V. and others.

Smart Insulin Pens Market

DelveInsight’s ‘Smart Insulin Pens Market Insights, Competitive Landscape and Market Forecast-2026’ report delivers an in-depth understanding of Smart Insulin Pens and the historical and forecasted Smart Insulin Pens market trends, market drivers, market barriers and key companies involved such as Novo Nordisk, DiabNext, InsulCloud, Medtronic, Companion Medical, Biocorp, Bigfoot Medical, Emperra GmbH E-Health Technologies, and others.

Insulin Delivery Devices Market

Insulin Delivery Devices Market is anticipated to expand at a significant CAGR forecast till 2026 due to rising prevalence of diabetes across the globe. The report delivers an in-depth understanding of Insulin Delivery Devices and the historical and forecastedInsulin Delivery Devices market trends, market drivers, market barriers and key companies involved such as Biocon Ltd., Eli Lilly and Company, Insulet Corporation, Abbott, Terumo, CeQur, EOFLOW CO., LTD, European Pharma Group BV, Roche, Sanofi, Hindustan Syringes & Medical Devices Ltd, Ocean (Hangzhou) Medical Technology Co Ltd, Owen Mumford, and others.

Interested to know more about the breakthrough happenings? Take a look at the posts below

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News

CONTACT: Contact Us

Shruti Thakur

info@delveinsight.com

+1(919)321-6187

www.delveinsight.com

關注我們Facebook專頁
    相關新聞
      更多瀏覽